Logo image of VIVS

VIVOSIM LABS INC (VIVS) Stock Fundamental Analysis

NASDAQ:VIVS - US68620A3023 - Common Stock

2.52 USD
+0.18 (+7.69%)
Last: 9/3/2025, 6:38:08 PM
2.5 USD
-0.02 (-0.79%)
After Hours: 9/3/2025, 6:38:08 PM
Fundamental Rating

4

Overall VIVS gets a fundamental rating of 4 out of 10. We evaluated VIVS against 542 industry peers in the Biotechnology industry. VIVS has a great financial health rating, but its profitability evaluates not so good. VIVS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year VIVS was profitable.
In the past year VIVS has reported a negative cash flow from operations.
VIVS had negative earnings in each of the past 5 years.
In the past 5 years VIVS always reported negative operating cash flow.
VIVS Yearly Net Income VS EBIT VS OCF VS FCFVIVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

VIVS's Return On Assets of -16.59% is fine compared to the rest of the industry. VIVS outperforms 79.52% of its industry peers.
The Return On Equity of VIVS (-20.83%) is better than 83.76% of its industry peers.
Industry RankSector Rank
ROA -16.59%
ROE -20.83%
ROIC N/A
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
VIVS Yearly ROA, ROE, ROICVIVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

VIVS's Gross Margin of 97.89% is amongst the best of the industry. VIVS outperforms 97.23% of its industry peers.
VIVS's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for VIVS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
VIVS Yearly Profit, Operating, Gross MarginsVIVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

7

2. Health

2.1 Basic Checks

VIVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VIVS has been reduced compared to 1 year ago.
VIVS has less shares outstanding than it did 5 years ago.
There is no outstanding debt for VIVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VIVS Yearly Shares OutstandingVIVS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
VIVS Yearly Total Debt VS Total AssetsVIVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

VIVS has an Altman-Z score of -41.41. This is a bad value and indicates that VIVS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -41.41, VIVS is not doing good in the industry: 91.33% of the companies in the same industry are doing better.
VIVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -41.41
ROIC/WACCN/A
WACC9.86%
VIVS Yearly LT Debt VS Equity VS FCFVIVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 4.52 indicates that VIVS has no problem at all paying its short term obligations.
With a Current ratio value of 4.52, VIVS perfoms like the industry average, outperforming 50.37% of the companies in the same industry.
VIVS has a Quick Ratio of 4.52. This indicates that VIVS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.52, VIVS is in line with its industry, outperforming 51.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.52
Quick Ratio 4.52
VIVS Yearly Current Assets VS Current LiabilitesVIVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

VIVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 297.92%, which is quite impressive.
The Revenue has grown by 94.52% in the past year. This is a very strong growth!
Measured over the past years, VIVS shows a very negative growth in Revenue. The Revenue has been decreasing by -42.03% on average per year.
EPS 1Y (TTM)297.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-397.81%
Revenue 1Y (TTM)94.52%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%-5.13%

3.2 Future

VIVS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.30% yearly.
The Revenue is expected to grow by 16.82% on average over the next years. This is quite good.
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VIVS Yearly Revenue VS EstimatesVIVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 1M 2M 3M 4M
VIVS Yearly EPS VS EstimatesVIVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2024 2025 2026 2027 -20 -40 -60 -80 -100

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 0.92 indicates a rather cheap valuation of VIVS.
VIVS's Price/Earnings ratio is rather cheap when compared to the industry. VIVS is cheaper than 99.63% of the companies in the same industry.
VIVS's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.84.
VIVS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.92
Fwd PE N/A
VIVS Price Earnings VS Forward Price EarningsVIVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIVS Per share dataVIVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

VIVS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as VIVS's earnings are expected to decrease with -6.30% in the coming years.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y-6.3%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VIVS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVOSIM LABS INC

NASDAQ:VIVS (9/3/2025, 6:38:08 PM)

After market: 2.5 -0.02 (-0.79%)

2.52

+0.18 (+7.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/bmo
Earnings (Next)N/A N/A
Inst Owners2.58%
Inst Owner ChangeN/A
Ins Owners0.6%
Ins Owner ChangeN/A
Market Cap6.55M
Analysts45.71
Price TargetN/A
Short Float %1.69%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-7.06%
Min Revenue beat(2)-22.82%
Max Revenue beat(2)8.7%
Revenue beat(4)1
Avg Revenue beat(4)-22.23%
Min Revenue beat(4)-46.52%
Max Revenue beat(4)8.7%
Revenue beat(8)2
Avg Revenue beat(8)-39.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.92
Fwd PE N/A
P/S 46.14
P/FCF N/A
P/OCF N/A
P/B 0.69
P/tB 0.69
EV/EBITDA N/A
EPS(TTM)2.75
EY109.13%
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-4.01
FCFYN/A
OCF(TTM)-4.01
OCFYN/A
SpS0.05
BVpS3.67
TBVpS3.67
PEG (NY)0.35
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.59%
ROE -20.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.89%
FCFM N/A
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.52
Quick Ratio 4.52
Altman-Z -41.41
F-Score5
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)52.61%
Cap/Depr(5y)295.14%
Cap/Sales(3y)51.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)297.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-397.81%
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)94.52%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%-5.13%
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.95%
OCF growth 3YN/A
OCF growth 5YN/A